Список литературы

Поставить закладку

Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognos- tic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214–2221.;
Hudis CA, Van Belle S, Chang J, Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. Oncologist 2004; 9(Suppl 5): 55–69;
Dicato M., Plawny L., Diederich M. Anemia in Cancer // Ann. Oncol. 2010. Vol. 21, No Supp. 7. P. 167–172;
Dallalio G., Law E., Means R.T. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations // Blood. Blood, 2006. Vol. 107, No 7. P. 2702–2704;
Dicato M. Anemia in Cancer: Some Pathophysiological Aspects // Oncologist. Alphamed Press, 2003. Vol. 8, No S1. P. 19–21.;
Кулибаба Т.Г., Пчелин И.Ю., Слепых Л.А. Особенности анемического синдрома у онкологических пациентов // Juvenis Scientia, 2018. - № 9 – С. 10-16
Ludwig H., Van Belle S., Barrett-Lee P., Birgegrd G., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–2306
Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance sta- tus, disease status and anemia. Ann Oncol 2013; 24: 1886–1892.
Delarue R, Tilly H, Salles GA et al. Iron parameters and relation to prog- nosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study. Blood 2013; 122 (Abstr 2202).
Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–2448;
Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979–986.;
Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888–895.;
Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improv- ing therapy. Br J Cancer 2001; 84(Suppl 1): 31–37;
Becker P.S. et al. Hematopoietic growth factors. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 2.2020. 2020. P. 98.
Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies // Blood Rev. Churchill Livingstone, 2015. Vol. 29, No 5. P. 291–299;
Национальный стандарт Российской Федерации. Кровь донорская и ее компоненты: Руководство по применению компонентов донорской крови. ГОСТ Р 53470-2009. 2010;
Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-Медиа, 2011. 304 с.;
Румянцев А.Г., Морщакова Е.Ф., Павлов А.Д. Эритропоэтин: биологические свойства, возрастная регуляция эритропоэза, клиническое применение. М.: ГЭОТАР-МЕД, 2003. 400 с.;
Razzouk B.I. et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy // J. Clin. Oncol. J Clin Oncol, 2006. Vol. 24, No 22. P. 3583–3589.;
Bohlius J. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, No 15. P. 1336–1351.;
Bennett C.L. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia // JAMA - J. Am. Med. Assoc. JAMA, 2008. Vol. 299, No 8. P. 914–924.;
Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis- stimulating agents in tumor progression // Clinical Cancer Research. American Association for Cancer Research, 2011. Vol. 17, No 20. P. 6373–6380.;
(UK) N.C.G.C. Alternatives to blood transfusion for patients having surgery: Oral iron, IV iron and erythropoietin. National Institute for Health and Care Excellence (UK), 2015
King K.E. et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs // Transfusion. Transfusion, 2004. Vol. 44, № 1. P. 25–29.
Dzik W.H. Leukoreduction of blood components // Current Opinion in Hematology. Curr Opin Hematol, 2002. Vol. 9, № 6. P. 521–526.
Rühl H., Bein G., Sachs U.J.H. Transfusion-Associated Graft-Versus-Host Disease // Transfusion Medicine Reviews. Transfus Med Rev, 2009. Vol. 23, № 1. P. 62–71.
Dwyre D.M., Holland P. V. Transfusion-associated graft-versus-host disease // Vox Sanguinis. Vox Sang, 2008. Vol. 95, № 2. P. 85–93.
Win N, Almusawy M, Fitzgerald L, et al. Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U-patients with anti-U. Transfusion. 2019;59(6):1916–1920. doi: 10.1111/trf.15230.
Губанова М.Н., Серба И.К., Шестаков Е.А., и др. Эволюция переливания крови в Пироговском центре // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. — 2017. — Т.12. — No4 (часть 2). — С. 90–92. [Gubanova MN, Serba IK, Shestakov EA, et al. Blood transfusion evolution in the Pirogov center. Bulletin of Pirogov National Medical & Surgical Center. 2017; 12(4 Pt 2):90–92. (In Russ).]

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница

Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов, инструкции по применению лекарственного препарата

Приложение Б. Алгоритмы действий врача

Приложение В. Информация для пациента

Данный блок поддерживает скрол*